Sleep Disruption Induced Impairments in Bone Formation

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

12 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-01-17

Study Completion Date

2020-03-16

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a small intervention study with healthy males aged 20-65 years old who habitually sleep 7-9 hours/night.This study investigates if and how sleep restriction, independent of circadian misalignment (e.g. shift work, jet lag), induces a decrease in the bone formation marker Procollagen I Intact N-Terminal Propeptide (PINP). The specific aim is to evaluate the mechanistic underpinnings for the relationship between sleep restriction and suppression of bone formation. The study will enroll 12 healthy male participants and have a two-week intervention after enrollment.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Fragmented Sleep, Pain, and Biomechanics

NCT06336109

Pain Healthy Sleep Disturbance

COMPLETED NA

Neurobehavioral Effects of Partial Sleep Deprivation

NCT02128737

Control 1 Night Recovery Sleep 3 Nights Recovery Sleep +1 more

COMPLETED NA

Sleeping Habits on Performance Following Sleep Deprivation

NCT05942664

Sleep Athletic Performance Hemodynamics

COMPLETED NA

Lagged Relationships Between Sleep, Balance, and Cognition in Older Adults

NCT06584136

Aging

COMPLETED

Sleep Deprivation and Energy Balance

NCT01334788

Sleep Deprivation

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Subjects are their own controls, with baseline measurements serving as the control values prior to intervention.

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Sleep Deprivation

Group Type EXPERIMENTAL

Sleep Deprivation

Intervention Type BEHAVIORAL

Participants in this arm will sleep for 8 hours at their habitual time for 1 week outpatient. Food will be provided for the outpatient week by the study. After the outpatient week participants will check into our inpatient Clinical Translational Research Center (CTRC) for a 9 day inpatient stay. During their inpatient stay participants will be sleep restricted to a 5 hour/night sleep opportunity for nights 2-7 of their inpatient stay. Outcome measures include a 24-hour serum draw (urine and blood) which will occur on night 1 (pre) and night 8 (post). Patients will be given a 10 + hour recovery sleep period on night 8 of their inpatient stay.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Sleep Deprivation

Participants in this arm will sleep for 8 hours at their habitual time for 1 week outpatient. Food will be provided for the outpatient week by the study. After the outpatient week participants will check into our inpatient Clinical Translational Research Center (CTRC) for a 9 day inpatient stay. During their inpatient stay participants will be sleep restricted to a 5 hour/night sleep opportunity for nights 2-7 of their inpatient stay. Outcome measures include a 24-hour serum draw (urine and blood) which will occur on night 1 (pre) and night 8 (post). Patients will be given a 10 + hour recovery sleep period on night 8 of their inpatient stay.

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

o Adult men aged 20-65 years old who habitually sleep 7-9 hours/night.

Exclusion Criteria

* Regularly go to sleep after midnight;
* Shift work 1 year prior to study;
* Travel \>1 time zone 4 weeks prior to study or need to travel during study;
* More than moderate activity level (\>3 days of exercise per week \>30 min of exercise per session);
* Current smokers (or within the previous year of study);
* Positive drug test at screening or laboratory admission;
* BMI \> 30 kg/m2;
* Individuals who are concurrently participating in another research protocol that would influence their safe participation in this study. For example, participants involved in a study that requires blood draws or ingestion of experimental medication as this would increase the risk of participation in our study and/or compromise study results.
* Any clinically significant unstable medical or surgical condition within the last year (treated or untreated), including history of a clinically significant abnormality of the neurological system (including cognitive disorders or significant head injury) or any history of seizure (including febrile seizure-sleep loss has been used clinically to induce seizures in patients with epilepsy). Given the wide range of illnesses that are encountered in medical practice, it would not be possible to provide a comprehensive list of each and every disease that could serve as grounds for exclusion for the subject. However, the following is a list of illness categories that would certainly be grounds for exclusion: Connective Tissue and Joint Disorders; Neurologic/cognitive Disorders; Musculoskeletal Disorders; Immune Disorders; Chronobiologic Disorders; Cardiovascular Disorders; Respiratory Disorders; Kidney Disorders; Infectious Diseases; Hematopoietic Disorders; Neoplastic Diseases; and Endocrine and Metabolic Diseases.
* Self-reported or newly diagnosed medical condition that is still being investigated or is not under good control, including those identified on screening labs such as:

* Out-of-range values measured on a fasting blood sample: glucose \> 100 mg/dl, thyroid stimulating hormone \<0.5 or \>5.0 uU/ml, abnormal alkaline phosphatase \<39 or \>117 U/l, creatinine, or hemoglobin \<14.5 g/dl men
* Any clinically significant psychiatric condition, as defined by DSM-V. Individuals with a history of most psychiatric illnesses or psychiatric disorders will be excluded, such as but not limited to depression, anxiety, alcoholism, drug dependency, schizophrenic disorders, and personality disorders (performed by medical history and physician interview). However, a personal history of limited prior counseling, psychotherapy (e.g., for adjustment reactions) will NOT be exclusionary. Evaluation of Psychiatric/Psychological Suitability:

* Subjects must demonstrate a full understanding of the requirements and demands of the study.
* Each subject will complete psychological screening questionnaires. Exclusionary: Center for Epidemiological Studies Depression (CES-D) ≥ 16;. Subject responses to the CES-D are reviewed immediately and appropriate referrals are made if necessary.
* Individuals who are unaware of specific psychiatric diagnoses who have a history of having been treated with antidepressants, neuroleptic medications or major tranquilizers will be excluded from study.
* Use of anti-depressants or any like therapeutics prescribed by a physician is exclusionary
* Individuals with any clinically significant sleep disorder; Diagnosis or symptoms of sleep disorders (history of significant parasomnia as an adult \[night terrors, frequent sleep walking\], insomnia, including but not limited to hypersomnias such as apnea, periodic limb movements, narcolepsy). Sleep disorders will be screened by self-report and physician interview including use of validated sleep questionnaires (PSQI, Epworth sleepiness scale, and Berlin sleep questionnaire for sleep apnea).
* Individuals on medications known to affect bone turnover (e.g. glucocorticoids, osteoporosis medications);
* Use of medications/supplements/drugs that impact sleep or bone metabolism (such as but not limited to sleep medications, marijuana etc.) within one month (participants can be studied at a later date).
* Dwelling below Denver altitude (1,600 m) 6 months prior to testing;
* Greater than moderate caffeine (\>500 mg/day) or alcohol use (\>14 standard drinks/week or \>5 drinks in one sitting);
* Subjects with a history of heparin-induced thrombocytopenia (HIT) or an allergy to heparin;
* Inability to travel to the CU-AMC campus for study visits.
* Individuals with restrictive diets (e.g., vegan)
* Individuals with 25OHD \< 20 ng/mL;
* Individuals with eGFR \< 60 mL/min/1.73m2 as this is known to affect CTX measurements;
* T-score ≤ -2.5 (men ≥50 years old) or Z-score \< -2.0 (men \<50 years old) for bone mineral density (BMD) at the L-spine, femoral neck, or total hip on baseline DXA as compared to the DXA machine's normative database;
* Symptoms of active illness (e.g., fever); note that subject can be studied at a later date.

Minimum Eligible Age

20 Years

Maximum Eligible Age

65 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes